Markov, O.V.; Sen’kova, A.V.; Mohamed, I.S.; Shmendel, E.V.; Maslov, M.A.; Oshchepkova, A.L.; Brenner, E.V.; Mironova, N.L.; Zenkova, M.A.
Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS40 Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response. Pharmaceutics 2022, 14, 2542.
https://doi.org/10.3390/pharmaceutics14112542
AMA Style
Markov OV, Sen’kova AV, Mohamed IS, Shmendel EV, Maslov MA, Oshchepkova AL, Brenner EV, Mironova NL, Zenkova MA.
Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS40 Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response. Pharmaceutics. 2022; 14(11):2542.
https://doi.org/10.3390/pharmaceutics14112542
Chicago/Turabian Style
Markov, Oleg V., Aleksandra V. Sen’kova, Islam S. Mohamed, Elena V. Shmendel, Mikhail A. Maslov, Anastasiya L. Oshchepkova, Evgeniy V. Brenner, Nadezhda L. Mironova, and Marina A. Zenkova.
2022. "Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS40 Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response" Pharmaceutics 14, no. 11: 2542.
https://doi.org/10.3390/pharmaceutics14112542
APA Style
Markov, O. V., Sen’kova, A. V., Mohamed, I. S., Shmendel, E. V., Maslov, M. A., Oshchepkova, A. L., Brenner, E. V., Mironova, N. L., & Zenkova, M. A.
(2022). Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS40 Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response. Pharmaceutics, 14(11), 2542.
https://doi.org/10.3390/pharmaceutics14112542